Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molina, M. A.
Right arrow Articles by Clinton, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molina, M. A.
Right arrow Articles by Clinton, G. M.
Clinical Cancer Research Vol. 8, 347-353, February 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer1

Miguel A. Molina, Rosana Sáez2, Elizabeth E. Ramsey2, María-José Garcia-Barchino, Federico Rojo, Adam J. Evans, Joan Albanell, Edward J. Keenan, Ana Lluch, Javier García-Conde, José Baselga and Gail M. Clinton3

Laboratory of Oncology Research, Medical Oncology Service, Vall d’Hebron Hospital, 08035 Barcelona, Spain [M. A. M., J. A., J. B.]; Hematology and Medical Oncology Service, Hospital Clínico, 46010 Valencia, Spain [R. S., M-J. G-B., A. L., J. G-C.]; and Departments of Physiology and Pharmacology [E. E. R., E. J. K.] and Biochemistry and Molecular Biology [A. J. E., G. M. C.], Oregon Health Sciences University, Portland, Oregon 97201


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Background: The full-length receptor p185HER-2 undergoes a metalloprotease-dependent cleavage producing a membrane-associated fragment (p95HER-2) in cultured breast cancer cells. P95HER-2 has potentially enhanced signaling activity, but its expression and role in human breast cancer is poorly characterized.

Purpose: The purpose of this project was to characterize the expression of p95HER-2 in primary breast cancers and nodal metastasis, and to study association with clinicopathological factors.

Experimental Design: P95HER-2 and p185HER-2 were examined in 337 primary breast tumors and 81 metastatic lymph nodes by Western blot analysis, and tested for associations with other clinicopathological factors.

Results: P95HER-2 was present in 20.9% of primary tumors from node-negative patients, in 29.1% from patients with one to three metastatic nodes, and in 36.7% from patients with four or more metastatic nodes (P = 0.027). Whereas p185HER-2 overexpression was unrelated to nodal disease (P = 0.63), the odds of lymph node metastasis were enhanced 2.9-fold by the presence of p95HER-2 (48.8% of node-negative versus 73.5% of node-positive patients; P = 0.03; odds ratio = 2.9). P95HER-2 was more frequent in metastatic lymph nodes than in primary tumors (45.7% versus 26.7%; P = 0.0009), whereas p185HER-2 overexpression was similar in both (22.3% versus 23.5%; P = 0.933). P95HER-2 did not significantly correlate with patient age, tumor size, stage, histotype, or hormone receptor status.

Conclusions: P95HER-2 in primary tumors was related to extent of lymph node involvement and was enhanced in nodal tissue suggesting an important role as a marker or cause in breast cancer metastasis. Examination of the prognostic value of p95HER-2 in breast cancer and its coexpression with metalloprotease activity seem warranted.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
The HER (or ErbB) family of transmembrane tyrosine kinase receptors is composed of four members, HER1 to HER4 (1) . HER-2, a ligand-less Mr 185,000 receptor encoded by the neu protooncogene, is overexpressed in 25–30% of human breast cancers, and predicts a significantly lower survival rate and a shorter time to relapse in patients with lymph-node positive disease (2) . The significance of HER-2/neu in node-negative patients is controversial, and thus far, its clinical utility as a prognostic indicator is limited (2) .

Recent evidence indicates that HER-2 amplifies the signal provided by other receptors of the ErbB family by heterodimerizing with them, playing an important role in the signaling network that drives epithelial cell proliferation (3) . This fact, together with its extracellular accessibility and its overexpression in some human tumors, makes the HER-2 receptor an appropriate target for tumor-specific therapies. Several monoclonal antibodies directed against the HER-2 ECD4 specifically inhibit the growth of tumor cell lines overexpressing HER-2. One of them, termed trastuzumab, has been humanized and is an effective therapeutic agent against HER-2-overexpressing breast cancers (4, 5, 6, 7) .

The HER-2 receptor p185HER-2 undergoes a slow but activable proteolytic shedding of its ECD from the surface of HER-2-overexpressing tumor cells in culture (8, 9, 10) . The HER-2 ECD has been found in the serum of patients with advanced breast cancer where it correlates with recurrence (11) and with decreased responsiveness to endocrine therapy and chemotherapy (11, 12, 13, 14, 15, 16, 17, 18, 19) . Serum ECD has also been reported to neutralize the activity of anti-HER-2 antibodies targeted to the ECD such as trastuzumab (7 , 13) .

We have reported recently that proteolytic shedding of the HER-2 ECD from cultured tumor cells generates a Mr 95,000 membrane-associated fragment that has in vitro kinase activity and is tyrosine-phosphorylated (20 , 21) . This p95HER-2 fragment, which is missing its ECD, may have constitutive kinase activity and, thus, enhanced signaling potency in tumor cells. This view is suggested by studies showing that an engineered deletion of HER-2 ECD increases the tyrosine kinase activity and transforming efficiency of the resulting truncated protein (22 , 23) . Other lines of evidence support the concept that the ECD of tyrosine-kinase receptors constrains the kinase activity of their cytoplasmic region. First, several retroviral oncogenes code for receptors that lack most of the ECD resulting in production of constitutively active, membrane-bound receptor fragments (24) . Second, mutant epidermal growth factor receptors with NH2-terminal truncations, found in several human carcinomas, have enhanced oncogenic activity (25 , 26) . Third, ECD shedding of HER4 results in the formation of a membrane-truncated fragment that has tyrosine kinase activity, is tyrosine phosphorylated, and may act as a membrane-localized docking anchor for signaling molecules with SH2 domains (27) .

Despite the potential importance of the truncated p95HER-2 in oncogenic signaling, its expression and significance in human breast cancer has not been extensively evaluated. Recently, we described the presence of the NH2-terminally truncated, tyrosine phosphorylated p95HER-2 in a subset of primary human breast cancer tissues (20 , 21) . In our preliminary study, p95HER-2 appeared to be at higher levels in the primary tumors from patients with node-positive breast cancer (21) .

Therefore, the study presented here was designed to comprehensively analyze the possible role of p95HER-2 compared with the full length receptor in lymph node metastases, which is the strongest risk factor for disease recurrence and poor outcome in breast cancer (2) . To this end, we examined the expression of p95HER-2 and p185HER-2: (a) in metastatic lymph node tissue; and (b) in primary tumors from a well-characterized patient population stratified into groups that differed in the extent of lymph node involvement. The results of this study suggest a role for the truncated p95HER-2 distinct from the full length receptor in breast cancer metastasis.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Cells and Antibodies.
The BT474 cell line was obtained from the American Type Culture Collection (Rockville, MD) and grown in DMEM/F12 supplemented with 10% fetal bovine serum, 2 mM of glutamine, and 10 µg/ml insulin (all from Life Technologies, Inc. Ltd., Paisley, United Kingdom). The 17-3-1 cells (NIH3T3 cells transfected with HER-2/neu cDNA) were provided by Applied Biotechnology Inc. (Cambridge, MA) and cultured in DMEM supplemented with 5% fetal bovine serum containing 0.4 mg/ml geneticin (G418; Life Technologies, Inc. Ltd.). The antibody against the COOH terminus of p185HER-2/neu, anti-neu(C), has been described previously (28) . Secondary antibody, conjugated to horseradish peroxidase, was from Amersham Pharmacia Biotech (Little Chafont, United Kingdom) or from Bio-Rad (Hercules, CA).

Western Blot Analysis of p95 and p185 in Breast Cancer Tissues.
Breast tissues used in this study were surgical resection specimens obtained at Oregon Health Sciences University Hospital (Portland, OR) following procedures approved by the Institutional Review Board Committee on Human Research, at Hospital Clínico Universitario of Valencia (Spain) and at Vall d'Hebron Hospital of Barcelona (Spain) following Institutional Guidelines. Breast tumor samples were analyzed as described previously (21) . Several controls and extraction procedures were conducted previously to characterize p95 and to ensure that it was not generated as a degradation artifact (20 , 21) . About 0.1 g of tumor tissue, which had been fresh-frozen and stored at -80°C, was minced on dry ice, and suspended in buffer containing protease inhibitors (1% aprotinin, 2 mM of phenylmethylsulfonyl fluoride, and 10 µg/ml leupeptin) and a phosphatase inhibitor (2 mM of sodium orthovanadate). After homogenization and fractionation, equal amounts of protein from each sample (20 µg) were resolved under denaturing and reducing conditions by SDS-PAGE in 8% gels. Each gel also contained 3 µg of protein from extracts of 17-3-1 and 4-aminophenylmercuric acetate-treated BT474 cells (20) to mark the migration of the bands and to provide a standard for the entire study. Electrophoretic transfer to nitrocellulose membranes (Bio-Rad) was followed by immunoblotting with the anti-neu(C) antibody. Finally, membranes were incubated with an antirabbit secondary antibody conjugated to horseradish peroxidase, which was detected by chemiluminescence (Pierce, Rockford, IL) and exposure to film.

HER-2 Protein Detection.
The samples were arbitrarily scored as p185HER-2 overexpressers if the p185HER-2 signal could be detected by 1-min exposure of the film and if the signal was greater than or equal to the p185 level in 3 µg of 17-3-1 cells or BT-474. Specimens were scored as positive for p95HER-2 if this band was detected after a 15-min exposure of the membrane to the film. The levels of p95HER-2 in tumor samples were usually lower than those of p185HER-2. Because of the high titer of the primary antibody, there were rarely any background bands.

Clinical Data.
A computer database, coded to protect the identity of the individual, was compiled containing clinical information on each patient including age, nodal status, histotype, and size of the primary tumor, age of the patient, stage of disease at diagnosis, ER and PR levels. The type of tumor of the specimens were as follows: 74.4% infiltrating ductal, 6.5% infiltrating lobular, 6.0% nonspecific adenocarcinoma, 3.5% mixed ductal/lobular, 2% medullary, and 7.5% other (mucinous, papillary, inflammatory, and so forth).

Statistical Analysis.
Associations between variables were determined by {chi}2 analysis using StatView by SaS Institute Inc. Strength of association for study comparisons were calculated as OR and 95% CI using standard formulas. All of the Ps reported are two-sided.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
p185 and p95HER-2 Levels in Primary Breast Tumor Tissue.
Tumor tissues (n = 337) collected in three different hospitals from the United States (Oregon Health Sciences University Hospital) and Spain (Hospital Clínico of Valencia and Vall d’Hebron Hospital of Barcelona) were examined for HER-2/neu proteins by Western analysis using an antibody that recognizes the receptor COOH terminus (28) . As reported previously in numerous studies, there were distinct expression patterns of p185 in the breast cancer samples (Table 1Citation ; Fig. 1Citation ). Analysis of 40 tumor samples revealed that the tumors with high p185 levels, determined by Western blot analysis, showed moderate or intense complete membrane IHC staining in >10% of tumor cells. This suggested that a similar group of HER-2-overexpressing samples were identified by Western blot analysis and by immunohistochemistry.


View this table:
[in this window]
[in a new window]
  		Table 1 p95HER-2 and p185HER-2 expression in 337 primary breast cancersa

 


View larger version (44K):
[in this window]
[in a new window]
  		Fig. 1. Western blotting analysis of 24 breast cancer tissues. Tissues were extracted and subjected to Western blotting with anti-HER-2 as described in "Materials and Methods." Of the 337 tumors analyzed, only 24 of them are presented, representative of samples expressing no HER-2 forms (V3377, V127, B03, P57), only p185 HER-2 (V2039, V3241, B04, B01, B44, P19, P21, P58, P59, P60), or p185 and p95 HER-2 (V49, V649, V84, V36, B08, P81, P12, P22, P80, P62). Samples are also representative of tumors expressing no p185 HER-2 (V3377, V127, B03, P57), low or moderate (P81, P19, P80, P58, P59, V694, V2039, V84, V36, B04), or high p185HER-2 levels (V49, V3241, B08, B01, B44, P12, P21, P22, P60 and P62). In most tumors expressing both HER-2 forms, the amount of p95 was lower or comparable with p185 (as in V49, V649, V84, B08, P12, P22, P62); only in some cases was the truncated fragment present at higher levels than the full-length receptor (as in V36 or P80). A control lane is also represented (BT) containing 3 µg of protein from an APMA-induced (20) BT-474 culture. Exposure time was 15'.

 
Tumors were also heterogeneous for p95HER-2 expression. Western analyses revealed that 26.7% of the primary breast cancer samples expressed p95. To examine the association of p95 with p185HER-2, the samples were stratified into those that were negative for p185HER-2 or those that expressed low, moderate, or high levels of the full-length receptor. The truncated fragment was apparent in only 2.1% of the p185-negative tumors, in 19.5% of low, in 31.8% of moderate, and in 60% of tumors that were highly positive for p185HER-2 (P < 0.001; see Fig. 1Citation and Table 1Citation ). Therefore, p95 expression strongly correlated with p185 expression in tumor tissue.

Relationship of p95 and p185 Levels in Primary Tumor with the Extent of Lymph Node Involvement.
In a preliminary study, p95HER-2 expression was significantly higher in node-positive versus node-negative samples (21) . In the current study, we grouped the samples into three categories according to the number of metastatic lymph nodes detected in patients: zero, one to three, or four or more nodes affected. The frequency of p185 HER-2 overexpression in primary tumor in these three groups was 23.8%, 18.6%, and 22.8%, respectively (Table 2)Citation . Correlation analysis showed that p185HER-2 overexpression in primary tumors did not associate with lymph node status either when the three groups were considered (P = 0.630) or when patients that had four or more affected nodes were compared with those that were node-negative (P = 0.982; OR = 0.94; CI = 0.5–1.77).


View this table:
[in this window]
[in a new window]
  		Table 2 Relationship between p95HER-2 expression and p185HER-2 overexpression with extent of lymph node involvementa

 
The truncated p95 was detected in 20.9%, 29.1%, and 36.7% of patients having zero, one to three, and four or more nodes affected, respectively (Table 2)Citation . Overall, the expression of the truncated fragment was significantly associated with increased extent of lymph node involvement (P = 0.027). The proportion of primary tumors positive for p95HER-2 was significantly higher in patients that had four or more positive nodes compared with those that were node-negative (P = 0.013; OR = 2.19; CI = 1.22–3.94).

Relationship of p95 Positivity and Lymph Node Status in the p185HER-2-overexpressing Group.
Whereas ~60% of the tumors that overexpressed p185HER-2 were also positive for p95 (Table 1)Citation , p185 overexpression did not correlate with the extent of lymph-node metastasis (Table 2)Citation . Therefore, we assessed whether the presence or absence of p95 in the p185 HER-2-overexpressing tumors (n = 78) affected the relationship with lymph node status (Table 3)Citation . In this group, we found that 48.8% of the node-negative patients expressed p95, whereas the truncated fragment was present in 73.5% of node-positive patients. Therefore, p185HER-2 overexpression in the absence of p95 correlated with node-negative disease, whereas in the presence of p95, there was an association with lymph node-positive disease (P = 0.03; OR = 2.92; CI = 1.10–7.75).


View this table:
[in this window]
[in a new window]
  		Table 3 Relationship between p95HER-2 expression and lymph node status in the group that overexpresses p185HER-2a

 
Relationship between p95, p185, and Other Prognostic Factors in Primary Breast Cancer.
We analyzed the possible association of p95 and p185 expression levels with several clinical parameters (Table 4)Citation known to be risk factors (2) . There was no significant association of either p95 or p185 overexpression with ER or PR status (P < 0.1). Moreover, p95 and p185 were at similar levels in tumors from patients that were less than or greater than age 60 years (P < 0.1). Stratification of patients into groups based on stage of the disease revealed no significant difference in p95 or p185 in these different groups (P >= 0.1). Moreover, neither of the two HER-2 forms were significantly elevated in large (>3 cm) tumors (P > 0.1). Finally, when the samples were grouped into infiltrating ductal versus other histological subtypes, there was no significant difference in p185 overexpression (P > 0.1) nor p95 expression in the two groups (P = 0.08).


View this table:
[in this window]
[in a new window]
  		Table 4 Relationship between p95HER-2 expression and p185HER-2 overexpression with other prognostic factorsa

 
Expression of p95 and p185HER-2 in Metastatic Nodes.
To additionally evaluate the involvement of p95 and p185HER-2 in metastasis, we examined whether the expression of either of the HER-2 forms was altered in breast cancer tissue obtained from metastatic lymph nodes. The truncated fragment was present in 45.7% of metastatic nodes compared with 26.7% of samples from primary tumors (P = 0.0009; OR = 2.31; CI = 1.4–3.8; Table 5Citation ). In contrast, p185 overexpression was not significantly different in metastatic node tissue relative to primary tumor, 22.3% versus 23.5% (P = 0.933; OR = 1.07; CI = 0.6–1.9). This is the first time that an alternative form of the HER-2 receptor has been found to be elevated in metastatic tissue.


View this table:
[in this window]
[in a new window]
  		Table 5 p95HER-2 expression and p185HER-2 overexpression in primary breast cancer and in metastatic nodesa

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
In this report, we describe the expression of full-length (p185) and NH2-terminal truncated (p95) HER-2 receptor by Western blot analysis in a panel of 337 primary breast cancer samples and in 81 samples from metastatic nodes. Breast tumors were found to show different expression patterns for the two HER-2 receptor forms. An important conclusion of our study is that the significance of p95 and p185HER-2 in regard to breast cancer metastasis to the lymph nodes is different. Thus, whereas p95HER-2 expression was significantly more frequent in tissue from metastatic nodes, and its presence in primary tumor correlated with the extent of lymph node metastasis; p185HER-2 overexpression was equally probable in primary versus metastatic tissue and in node-negative versus node-positive patients.

Whereas almost all of the samples (98%) that contained p95 showed detectable levels of p185HER-2, some tumors expressed p185 but not p95 (see Fig. 1Citation and Table 1Citation ), suggesting that the level of truncated receptor is regulated. Our previous studies have demonstrated that p95HER-2 is generated by proteolytic shedding of the receptor ECD in cultured breast carcinoma cells (20 , 21) . A similar processing event may be responsible for generation of p95 in breast tumor tissue, because the shed ECD has also been found in the serum of patients with HER-2-positive breast cancer (16, 17, 18, 19) . However, the possibility remains that p95 or the ECD in serum could be the product of alternative HER-2 transcripts (29) . Some additional evidence supports the interpretation that p95 in tumors is generated by shedding. First, the truncated HER-2 in tumors exactly comigrates in gels with the p95HER-2 generated by proteolytic cleavage in cultured cells. Second, an alternative HER-2 transcript that expresses a product resembling p95 has not been found. The protease responsible for the HER-2 shedding from breast carcinoma cells has not yet been identified but is likely a metalloprotease (20 , 21 , 30) . Identification of this sheddase will be important to understand the role it might play in regulation of HER-2 cleavage and generation of the p95 fragment.

Western analysis is currently the only method that can discriminate between the two HER-2 protein forms. IHC analysis, most commonly used for clinical detection of HER-2 protein expression, cannot discern the presence of p95HER-2. Western blotting, in contrast to IHC, involves analysis of block tissue and is, therefore, incapable of discriminating the specific cells in the tumor tissue that express the HER-2 protein. Because p95 and p185HER-2 are detected only in carcinoma epithelial cells (20) , those tissue samples highly contaminated with stroma would tend to show low levels of both HER-2 protein forms. When we analyzed 40 tumors by IHC, the results were coincident with those obtained by Western blotting for p185HER-2 overexpression, suggesting that false negatives are not present in a significant proportion.

We found p185HER-2 overexpression in 22.3% of primary breast tumors examined by Western analysis (Table 5)Citation , which is within the range of 20–35% reported in most studies using a variety of methods of detection (2 , 31) . Lymph node metastases overexpressed the full-length receptor to a similar extent (23.5%). This is in agreement with a recent study (32) that evaluated p185HER-2 in primary and metastatic tissue from 196 breast cancer patients. The receptor status of primary tumors was found to be maintained in the majority of their metastases. Therefore, a conclusion of this study (32) was that loss of p185HER-2 expression in metastatic tissue was not likely responsible for failure to respond to trastuzumab therapy in a significant fraction of HER-2-overexpressing patients. We report here that, in contrast to the full length receptor, p95HER-2 is more frequently expressed in lymph node metastatic tissue (45.7%) than in primary tumors (26.7%). If the truncated kinase p95 has a role in metastasis, as our study suggests, its presence may identify patients that are unlikely to respond to trastuzumab. Small molecule tyrosine kinase inhibitors may prove to be effective against p95-positive breast cancer.

The presence of axillary lymph node metastasis as well as tumor size are the most important prognostic factors for DFS and OS in women with breast carcinoma (33) . Detection of positive nodes affects more treatment decisions than any other single factor (2) . According to our results, neither p185HER-2 overexpression nor moderate expression in the primary tumor significantly correlated with lymph node metastasis (see Tables 2Citation and 3Citation ). The numerous studies addressing whether HER-2 overexpression is associated with node status have yielded conflicting results. Most of the more recent reports, some of them involving >800 patients (34, 35, 36) , have not found a significant association of p185HER-2 overexpression assessed by IHC (35, 36, 37, 38) or HER-2/neu gene amplification (34 , 39) with lymph node involvement. Only a few authors have reported a significant correlation between these two parameters (40 , 41) . Our results, showing that only the truncated p95 HER-2 associates with node involvement, may help clarify why previous studies, which did not discern the presence of p95, failed to find consistent correlations between HER-2 expression and lymph node metastasis.

A possible explanation for the association of p95 but not p185HER-2 with metastasis is that the truncated fragment has enhanced biological potency. In vitro studies have demonstrated that engineered deletion of the ECD increases the kinase activity and transforming efficiency of the resulting HER-2 truncated protein (22 , 23) . Moreover, p95 HER-2, generated by proteolytic shedding, is tyrosine phosphorylated and has kinase activity (20 , 21) , two properties associated with signaling activity. On the basis of our findings we propose that overexpression of the full-length HER-2 receptor may promote the initial events of abnormal proliferation in the primary tumor but, in the absence of p95, these tumors are less likely to metastasize. An alternative explanation is that p95 could mark tumors that express a particular protease that is relevant for metastasis, although based on the above-mentioned biochemical properties of p95, we consider this second possibility rather improbable.

Neither the presence of p95 in primary breast tumor nor the overexpression of p185HER-2 correlated with other prognostic markers in this study such as stage of the disease, tumor size, histological subtype, or hormone receptor status (Table 4)Citation . The lack of correlation with tumor size may explain why there was no association between p95HER-2 and stage, which is based on tumor size as well as presence of metastatic nodes. Several studies have failed to find an association between HER-2 overexpression and stage or tumor size (39 , 41, 42, 43) , whereas only a few authors have reported a significant correlation between these two parameters (35 , 38) . Interestingly, in all of the cases where only node-negative patients were analyzed, p185HER-2 did not correlate with tumor size (44, 45, 46) . Noncoincident results also exist regarding the association of HER-2 overexpression and tumor stage (39 , 40 , 47) , or ER and PR negativity (34 , 38 , 39 , 42 , 45 , 48) . Finally, in the limited number of studies where histotype of the tumor was determined, it did not relate with HER-2 overexpression (34 , 46) .

Of the new cases of breast cancer that occur in the United States annually, about two-thirds have node-negative disease (49) . Approximately 30% of patients diagnosed with node-negative breast cancer will relapse within 10 years after surgery and, therefore, may benefit from adjuvant systemic therapy (50) . Current prognostic indicators, such as histomorphological and clinical factors, are not sufficiently sensitive to identify this subgroup of patients, and there is no singular predictor of outcome for node-negative disease. Therefore, it remains a challenge to identify new markers with predictive value to differentiate the node-negative patients at the greatest risk of relapse. Although it seems to be widely accepted that c-erbB-2 amplification and overexpression in tumor cells is associated with a worse DFS and OS in node-positive patients, the prognostic value in node-negative patients is still controversial (2) . Some studies have not found an association between HER-2 amplification or overexpression and DFS or OS in node-negative breast cancer patients (35 , 42 , 50 , 51) , whereas others have described a correlation with DFS (33 , 44 , 46) or with OS and DFS (40 , 45 , 49) . In some reports, the significance has been restricted to subsets of lymph node-negative patients (52 , 53) additionally emphasizing the limited prognostic value of HER-2. These discrepancies have been attributed to methodological differences (reviewed in Ref. 31 ) or insufficient statistical power (2 , 45) . According to our results, p95HER-2 in the primary tumor indicates a 2.9-fold increased chance of metastasis, which is the single strongest predictor of poor outcome, in HER-2-overexpressing patients. Therefore, p95HER-2, which was detected in node-negative patients, could be of value in predicting outcome for this group. It will be important to conduct follow-up studies to determine the value of p95HER-2 in identifying node-negative breast cancer patients at high risk of developing recurrent disease.


   ACKNOWLEDGMENTS
 
We thank Baoyu Lin of Oregon Health Sciences University for technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the National Cancer Institute Grant and Grant No. 9346 from the Department of the Army (to G. M. C.), and by Spanish Health Ministry Grant "Fondo de Investigación Sanitaria" (99/0020-01; to J. A., A. L., J. G-C., J. B.). Back

2 These two authors contributed equally to the paper. Back

3 To whom requests for reprints should be addressed at Department of Biochemistry and Molecular Biology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098. Phone: (503) 494-2543; Fax: (503) 494-8393; E-mail: clinton{at}ohsu.edu Back

4 The abbreviations used are: ECD, ectodomain; ER, estrogen receptor; PR, progesterone receptor; OR, odds ratio; CI, confidence interval; IHC, immunohistochemical; DFS, disease-free survival; OS, overall survival. Back

Received 5/22/01; revised 10/31/01; accepted 11/15/01.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Groenen L. C., Nice E. C., Burgess A. W. Structure-function relationships for the EGF/TGF-{alpha} family of mitogens. Growth Factors., 11: 235-257, 1994.[Medline]
  2. Henderson I. C., Patek A. J. The relationship between prognostic and predictive factor in the management of breast cancer. Breast Cancer Res. Treat., 52: 261-268, 1998.[CrossRef][Medline]
  3. Klapper L. N., Kirschbaum M. H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res., 77: 25-79, 2000.[Medline]
  4. Carter P., Presta L., Gorman C. M., Ridgway J. B., Henner D., Wong W. L., Rowland A. M., Kotts C., Carver M. E., Shepard H. M. Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.[Abstract/Free Full Text]
  5. Fendly B. M., Winget M., Hudziak R. M., Lipari M. T., Napier M. A., Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER-2/neu gene product. Cancer Res., 50: 1550-1558, 1990.[Abstract/Free Full Text]
  6. Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.[Abstract]
  7. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER-2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.[Abstract/Free Full Text]
  8. Lin Y. L., Clinton G. M. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene, 6: 639-643, 1991.[Medline]
  9. Pupa S. M., Menard S., Morelli D., Pozzi B., De Palo G., Colnaghi M. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.[Medline]
  10. Zabrecky J. R., Lam T., McKenzie S. J., Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem., 266: 1716-1720, 1991.[Abstract/Free Full Text]
  11. Brandt-Rauf P. W. The c-erb transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat. Res., 333: 203-208, 1995.[Medline]
  12. Molina R., Zanon J. J., Filella X., Farrus B., Munoz R., Latre M. L., Pahisa J., Velasco M., Fernandez P., Estape J., Bassesta A. M. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA. Br. J. Cancer, 4: 1126-1131, 1996.
  13. Brodowicz T., Wiltschke C., Budinsky A. C., Krainer M., Steger G. G., Zielinski C. C. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int. J. Cancer., 73: 875-879, 1997.[CrossRef][Medline]
  14. Kandl H., Seymour L., Bezwoda W. R. Soluble c-erbB-2 fragment in serum correlates with disease state and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer., 70: 739-742, 1994.[Medline]
  15. Fehm T., Maimonis P., Katalinic A., Jager W. H. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology, 55: 33-38, 1998.[CrossRef][Medline]
  16. Leitzel K., Teramoto Y., Konrad K., Chinchilli V. M., Volas G., Grossberg H., Harvey H., Demers L., Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormonal therapy of breast cancer. J. Clin. Oncol., 13: 1129-1235, 1995.[Abstract]
  17. Yamauchi H., O’Neill A., Gelman R., Carney W., Tenney D. Y., Hosch S., Hayes D. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 18-25, 1996.[Abstract/Free Full Text]
  18. Colomer R., Montero S., Lluch A., Ojeda B., Barnadas A., Casado A., Massutí A., Cortés-Funes H., Lloveras B. Circulating HER-2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res., 6: 2356-2362, 2000.[Abstract/Free Full Text]
  19. Harris L. N., Trock B., Berris M., Esteva-Lorenzo F., Paik S. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc. Am. Soc. Clin. Oncol., 15: A96 1996.
  20. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. Trastuzumab (Herceptin), a humanized anti-HER-2 receptor monoclonal antibody, inhibits basal and activated HER-2 ectodomain cleavage in breast cancer cells. Cancer Res., in press, 2001.
  21. Christianson T. A., Doherty J. K., Lin Y. J., Ramsey E. E., Holmes R., Keenan E. J., Clinton G. M. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res., 15: 5123-5129, 1998.
  22. DiFiore P. P., Pierce J. H., Kraus M. H., Segatto O., King C. R., Aaronson S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.[Abstract/Free Full Text]
  23. Segatto O., King C. R., Pierce J. H., Di Fiore P. P., Aaronson S. A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol., 8: 5570-5574, 1988.[Abstract/Free Full Text]
  24. Rodrigues G. A., Park M. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev., 4: 15-24, 1994.[CrossRef][Medline]
  25. Moscatello D. K., Montgomery R. B., Sundareshan P., McDanel H., Wong M. Y., Wong A. J. ransformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene, 13: 85-96, 1996.[Medline]
  26. Moscatello D. K., Holgado-Maduraga M., Godwin A. K., Ramirez G., Gunn G., Zoltick P. W., Biegel J. A., Hayes R. L., Wong A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55: 5536-5539, 1995.[Abstract/Free Full Text]
  27. Vecchi M., Carpenter G. Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J. Cell. Biol., 139: 995-1003, 1997.[Abstract/Free Full Text]
  28. Lin Y. J., Li S., Clinton G. M. Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2/neu in the breast carcinoma line, BT474. Mol. Cell. Endocrinol., 69: 111-119, 1990.[CrossRef][Medline]
  29. Scott G. K., Robles R., Park J. W., Montgomery P. A., Daniel J., Holmes W. E., Lee J., Keller G. A., Li W., Fendly B. M., Wood W. I., Shepard M., Benz C. C. A truncated intracellular HER-2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell. Biol., 13: 2247-2257, 1993.[Abstract/Free Full Text]
  30. Codony-Servat J., Albanell J., Lopez-Talavera J. C., Arribas J., Baselga J. Cleavage of the HER-2 ectodomain is a pervanadate activable process that is inhibited by the tissue inhibitor of metalloproteases TIMP-1 in breast cancer cells. Cancer Res., 59: 1196-1201, 1999.[Abstract/Free Full Text]
  31. Fitzgibbons P. L., Page D. L., Weaver D., Thor A. D., Allred D. C., Clark G. M., Ruby S. G., O’Malley F., Simpson J. F., Connolly J. L., Hayes D. F., Edge S. B., Lichter A., Schnitt S. J. Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch. Pathol. Lab. Med., 124: 966-978, 2000.[Medline]
  32. Simon R., Nocito A., Hubsher T., Bucher C., Torhorst J., Scharml P., Bubendorf L., Mihatsch M. M., Moch H., Wilber K., Schotzau A, Kononen J., Sauter G. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl. Cancer. Inst., 93: 1141-1146, 2001.[Abstract/Free Full Text]
  33. Harris J. R., Lippman M. E., Veronesi U., Willet W. Breast cancer. N. Engl. J. Med., 327: 473-480, 1992.[Medline]
  34. Torregrosa D., Bolufer P., Lluch A., Lopez J. A., Barragan E., Ruiz A., Guillem V., Munarriz B., Garcia-Conde J. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin. Chim. Acta., 262: 99-119, 1997.[CrossRef][Medline]
  35. Thor A. D., Liu S., Edgerton S., Moore D., Kasowitz K. M., Benz C. C., Stern D. F., DiGiovanna M. P. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu). A study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol., 18: 3230-3239, 2000.[Abstract/Free Full Text]
  36. Barth A., Craig P. H., Silverstein M. J. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer (Phila.), 79: 1918-1922, 1997.[CrossRef][Medline]
  37. Mittra I., Redkar A. A., Badwe R. A. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J. Surg. Oncol., 60: 106-111, 1995.[Medline]
  38. Beckmann M. W., Niederacher D., Massenkeil G., Tutschek B., Beckmann A., Schenko G., Schnurch H-G., Bender H. G. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction in recurrence or survival in breast cancer patients. Oncology, 53: 441-447, 1996.[Medline]
  39. Scorilas A., Yotis J., Stravolemos K., Gouriotis D., Keramopoulos A., Ampela K., Talieri M., Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res., 15: 1543-1548, 1995.[Medline]
  40. Depowski P. L., Brien T. P., Sheehan C. E., Stylos S., Johnson R. L., Ross J. S. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Am. J. Clin. Pathol., 112: 459-469, 1999.[Medline]
  41. Tetu B., Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Cancer (Phila.), 73: 2359-2365, 1994.[CrossRef][Medline]
  42. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol., 7: 1120-1128, 1989.[Abstract]
  43. Singleton T. P., Strickler J. G. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu., 27: 165-198, 1992.
  44. Paterson M. C., Dietrich K. D., Danyluk J., Paterson A. H., Lees A. W., Jamil N., Hanson J., Jenkins H., Krause B. E., McBlain W. A., Slamon D. J., Fourney R. M. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res., 51: 556-567, 1991.[Abstract/Free Full Text]
  45. Press M. F., Bernstein L., Thomas P. A., Meisner L. F., Zhou J. Y., Ma Y., Hung G., Robinson R. A., Harris C., El-Naggar A. S., Slamon D. J., Phillips R. N., Ross J. S., Wolman S. R., Flom K. J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol., 15: 2894-2904, 1997.[Abstract]
  46. Andrulis I. L., Bull S. B., Blackstein M. E., Sutherland D., Mak C., Sidlofsky S., Pritzker K. P., Hartwick R. W., Hann W., Lickley L., Wilkinson R., Qizilbash A., Ambus U., Lipa M., Weizel H., Katz A., Baida M., Mariz S., Stoik G., Dacamara P., Strongitharm D., Geddie W., McCready D. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J. Clin. Oncol., 16: 1340-1349, 1998.[Abstract/Free Full Text]
  47. Agrup M., Stal O., Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res. Treat., 63: 23-29, 2000.[CrossRef][Medline]
  48. Carlomagno C., Perrone F., Gallo C., DeLaurentiis M., Lauria R., Morabito A., Pettinato G., Panico L., D’Antonio A., Bianco A. R., De Placido S. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol., 14: 2702-2708, 1996.[Abstract/Free Full Text]
  49. O’Malley F. P., Saad Z., Kerkvliet N., Doig G., Stitt L., Ainsworth P., Hundal H., Chambers A. F., Turnbull D. I., Bramwell V. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Hum. Pathol., 27: 955-963, 1996.[CrossRef][Medline]
  50. Harbeck N., Dettmar P., Thomssen C., Berger U., Ulm K., Kates R., Hofler H., Janicke F., Graeff H., Schmitt M. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br. J. Cancer., 80: 419-426, 1999.[CrossRef][Medline]
  51. Reed W., Hannisdal E., Boehler P. J., Gundersen S., Host H., Marthin J. The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. Cancer (Phila.), 88: 804-813, 2000.[CrossRef][Medline]
  52. Paik S., Hazan R., Fisher E. R., Sass R. E., Fisher B., Redmond C., Schlessinger J., Lippman M. E., King C. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol., 8: 103-112, 1990.[Abstract/Free Full Text]
  53. Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L., McGuire W. L. HER-2/neu in breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 1049-1056, 1992.[Abstract]



This article has been cited by other articles:


Home page
 JCOHome page
A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
J. Clin. Oncol., July 10, 2008; 26(20): 3317 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al.
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
J Natl Cancer Inst, April 18, 2007; 99(8): 628 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Rojo, L. Najera, J. Lirola, J. Jimenez, M. Guzman, M. D. Sabadell, J. Baselga, and S. R. y Cajal
4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis
Clin. Cancer Res., January 1, 2007; 13(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kalyankrishna and J. R. Grandis
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Saez, M. A. Molina, E. E. Ramsey, F. Rojo, E. J. Keenan, J. Albanell, A. Lluch, J. Garcia-Conde, J. Baselga, and G. M. Clinton
p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 424 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Climent, J. A. Martinez-Climent, D. Blesa, M. J. Garcia-Barchino, R. Saez, D. Sanchez-Izquierdo, P. Azagra, A. Lluch, and J. Garcia-Conde
Genomic Loss of 18p Predicts an Adverse Clinical Outcome in Patients with High-Risk Breast Cancer
Clin. Cancer Res., December 1, 2002; 8(12): 3863 - 3869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Frankel
New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002.
Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molina, M. A.
Right arrow Articles by Clinton, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molina, M. A.
Right arrow Articles by Clinton, G. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online